Neurogene stops Batten gene therapy after FDA denies request, dealing double dose of bad news Read more 

Incyte's $750M buyout rocked by pause on key trial, asset cull Read more 

Nearing potential FDA approval, BridgeBio shows additional positive data on ATTR-CM candidate acoramidis Read more 

The Hope & Anchor, Liverpool

Biotech & Beers

An agenda-free networking evening which provides opportunities for key people from companies working in or with the life sciences sector to network and socialise with [...]

Go to Top